$1.52 Billion is the total value of Casdin Capital, LLC's 37 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | SCIENCE 37 HOLDINGS INC | $0 | – | -225,000 | -100.0% | -0.04% | – | |
| ORIC | Exit | ORIC PHARMACEUTICALS INC | $0 | – | -601,515 | -100.0% | -0.23% | – |
| FDMT | Exit | 4D MOLECULAR THERAPEUTICS IN | $0 | – | -555,455 | -100.0% | -0.33% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -0.35% | – |
| PMVP | Exit | PMV PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -0.36% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -85,000 | -100.0% | -0.91% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -272,500 | -100.0% | -0.93% | – |
| Exit | TANGO THERAPEUTICS INC | $0 | – | -3,500,000 | -100.0% | -1.34% | – | |
| AGIO | Exit | AGIOS PHARMACEUTICALS INC | $0 | – | -785,000 | -100.0% | -1.47% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -800,000 | -100.0% | -2.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-21 |
| 4 | 2024-06-12 |
| 4 | 2024-06-05 |
| SC 13D/A | 2024-06-03 |
| 4 | 2024-05-31 |
| 4 | 2024-05-28 |
| 4 | 2024-05-28 |
| 4 | 2024-05-22 |
| SC 13D/A | 2024-05-22 |
| 4 | 2024-05-17 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.